Skip to Main Content

Paper Details

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Haematologica
202
2019
Author NameAffiliation
Emmanuel RaffouxUniversite Paris Diderot
Claude GardinUniversite Paris 13
Claude PreudhommeUniversite Lille, INSERM, Centre Hospitalier Universitaire Lille
Herv?? DombretUniversite Paris Diderot
  • 1 - 4

Datasets

Release 1.2